|
US5965362A
(en)
|
1992-03-04 |
1999-10-12 |
The Regents Of The University Of California |
Comparative genomic hybridization (CGH)
|
|
HU221001B1
(hu)
|
1994-03-17 |
2002-07-29 |
Merck Patent Gmbh. |
Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok
|
|
PT1256576E
(pt)
|
2000-02-15 |
2005-09-30 |
Astellas Pharma Inc |
Derivados de imidazolio fundidos
|
|
WO2002066058A1
(en)
|
2001-02-19 |
2002-08-29 |
Merck Patent Gmbh |
Modified anti-egfr antibodies with reduced immunogenicity
|
|
KR100945108B1
(ko)
|
2001-06-13 |
2010-03-02 |
젠맵 에이/에스 |
표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
KR101015034B1
(ko)
|
2003-04-15 |
2011-02-16 |
아스텔라스세이야쿠 가부시키가이샤 |
브롬화물 및 이의 결정
|
|
AR046639A1
(es)
|
2003-11-21 |
2005-12-14 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti- igfr1
|
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
|
BRPI0509580A
(pt)
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
|
JPWO2005111213A1
(ja)
|
2004-05-18 |
2008-03-27 |
学校法人 久留米大学 |
Myc標的遺伝子mimitin
|
|
US20060079494A1
(en)
|
2004-09-27 |
2006-04-13 |
Santi Daniel V |
Specific kinase inhibitors
|
|
JP2009515878A
(ja)
|
2005-11-12 |
2009-04-16 |
イーライ リリー アンド カンパニー |
抗egfr抗体
|
|
JP4806776B2
(ja)
|
2006-01-27 |
2011-11-02 |
国立大学法人 千葉大学 |
c−myc遺伝子転写抑制因子FIRのスプライシングバリアント又はイントロン2内の4塩基繰り返し配列による癌検出方法
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
諾華公司 |
吡咯并嘧啶化合物及其用途
|
|
EP2055304A1
(en)
|
2006-08-25 |
2009-05-06 |
Astellas Pharma Inc. |
Stabilized pharmaceutical composition
|
|
US8227605B2
(en)
|
2006-10-31 |
2012-07-24 |
Schering Corporation |
2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
|
|
US7618992B2
(en)
|
2006-12-29 |
2009-11-17 |
Astellas Pharma Inc. |
Method of treating cancer by co-administration of anticancer agents
|
|
CA2703979A1
(en)
|
2007-10-29 |
2009-05-07 |
Schering Corporation |
Heterocyclic ether and thioether derivatives and methods of use thereof
|
|
US8022057B2
(en)
|
2007-11-12 |
2011-09-20 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
WO2009146034A2
(en)
|
2008-03-31 |
2009-12-03 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
AU2009284098B2
(en)
|
2008-08-22 |
2012-03-29 |
Astex Therapeutics Ltd. |
Pyrrolopyrimidine compounds as CDK inhibitors
|
|
WO2010056931A1
(en)
|
2008-11-14 |
2010-05-20 |
Intelligent Oncotherapeutics, Inc. |
Methods for identification of tumor phenotype and treatment
|
|
US8710068B2
(en)
|
2009-01-19 |
2014-04-29 |
The Trustees Of The University Of Pennsylvania |
Method of treating cancer using a survivin inhibitor
|
|
CA2789696C
(en)
*
|
2010-02-25 |
2017-11-07 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
US20130035336A1
(en)
|
2010-04-13 |
2013-02-07 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
|
|
US8709419B2
(en)
*
|
2010-08-17 |
2014-04-29 |
Hoffmann-La Roche, Inc. |
Combination therapy
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
JP2014156400A
(ja)
|
2011-05-24 |
2014-08-28 |
Astellas Pharma Inc |
腫瘍の画像診断用標識誘導体
|
|
WO2012167099A1
(en)
|
2011-06-01 |
2012-12-06 |
Baylor College Of Medicine |
Biomarkers and therapy for cancer
|
|
FI20115876A0
(fi)
|
2011-09-06 |
2011-09-06 |
Turun Yliopisto |
Yhdistelmähoito
|
|
US20130122005A1
(en)
*
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
|
RU2014122048A
(ru)
|
2011-11-16 |
2015-12-27 |
Онкомед Фармасьютикалс, Инк. |
Мутации рецептора notch человека и их применение
|
|
WO2013148649A1
(en)
|
2012-03-26 |
2013-10-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Use of survivin antagonists in polyomavirus-related disease
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
EP2945628B1
(en)
|
2013-01-15 |
2020-04-15 |
Aragon Pharmaceuticals, Inc. |
Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
|
|
WO2014152358A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
US20160024591A1
(en)
|
2013-03-14 |
2016-01-28 |
Wake Forest University Health Sciences |
Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
|
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
|
US9913844B2
(en)
|
2013-03-21 |
2018-03-13 |
Novartis Ag |
Combination therapy
|
|
US9314460B1
(en)
|
2013-04-09 |
2016-04-19 |
Stc.Unm |
Method for cancer cell reprogramming
|
|
KR101514877B1
(ko)
|
2013-05-06 |
2015-04-24 |
조선대학교산학협력단 |
APE/Ref -1 및 JAG1/Notch의 대장암 진단용 마커로서의 용도
|
|
US20170080093A1
(en)
|
2013-10-22 |
2017-03-23 |
Tyme, Inc. |
Tyrosine Derivatives And Compositions Comprising Them
|
|
BR112016014481B1
(pt)
*
|
2013-12-20 |
2022-11-08 |
Biomed Valley Discoveries, Inc |
Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
|
|
US11013743B2
(en)
|
2013-12-20 |
2021-05-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of CDK and ERK inhibitors
|
|
US20200237758A1
(en)
|
2014-04-04 |
2020-07-30 |
Astrazeneca Ab |
Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
|
|
EP3131552B1
(en)
|
2014-04-16 |
2020-07-15 |
Signal Pharmaceuticals, LLC |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
|
SG11201610534UA
(en)
*
|
2014-06-16 |
2017-01-27 |
Worldwide Innovative Network |
Method for selecting personalized tri-therapy for cancer treatment
|
|
CN107073132B
(zh)
|
2014-10-06 |
2021-08-27 |
梅约医学教育与研究基金会 |
载体-抗体组合物及其制备和使用方法
|
|
BR112017025045A2
(pt)
|
2015-05-22 |
2018-08-07 |
Plexxikon Inc |
plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
|
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
CN107708734B
(zh)
|
2015-06-22 |
2022-01-11 |
詹森生物科技公司 |
用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
|
|
WO2017019279A1
(en)
|
2015-07-27 |
2017-02-02 |
Southern Research Institute |
Methods and compositions to treat cancers involving egfr
|
|
US20180243304A1
(en)
|
2015-08-28 |
2018-08-30 |
Novartis Ag |
Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
|
|
AU2016315878A1
(en)
|
2015-09-03 |
2018-03-29 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
EP3349774A4
(en)
|
2015-09-15 |
2019-03-27 |
Swedish Health Services |
METHOD AND COMPOSITE SHEETS FOR CHARACTERIZING GLOBALBLASTOMA MULTIFORM TUMORS AND CANCER STEM CELLS THEREOF
|
|
WO2017070475A1
(en)
|
2015-10-22 |
2017-04-27 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies
|
|
AU2017205478A1
(en)
|
2016-01-07 |
2018-06-28 |
Swadesh K. Das |
A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP)
|
|
WO2017143237A1
(en)
|
2016-02-17 |
2017-08-24 |
Acetylon Pharmaceuticals, Inc. |
Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs
|
|
TW201813644A
(zh)
*
|
2016-09-23 |
2018-04-16 |
江蘇恆瑞醫藥股份有限公司 |
酪胺酸激酶抑制劑在製備治療癌症藥物中的用途
|
|
WO2018127786A1
(en)
|
2017-01-06 |
2018-07-12 |
Oslo Universitetssykehus Hf |
Compositions and methods for determining a treatment course of action
|
|
CN106822905B
(zh)
|
2017-03-08 |
2019-05-17 |
暨南大学 |
含Survivin抑制剂和IRE1抑制剂的药物及用途
|
|
WO2018218633A1
(en)
|
2017-06-02 |
2018-12-06 |
Beijing Percans Oncology Co. Ltd. |
Combination therapies for treating cancers
|
|
US12571049B2
(en)
|
2018-03-21 |
2026-03-10 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes
|
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
|
WO2020034061A1
(en)
|
2018-08-13 |
2020-02-20 |
Beijing Percans Oncology Co., Ltd. |
Biomarkers for cancer therapy
|
|
WO2020036852A1
(en)
|
2018-08-13 |
2020-02-20 |
Beijing Percans Oncology Co. Ltd. |
Biomarkers for cancer therapy
|
|
WO2020097901A1
(en)
|
2018-11-16 |
2020-05-22 |
Beijing Percans Oncology Co. Ltd. |
Biomarkers for cancer therapy
|